RETROSPECTIVE REVIEW OF LETERMOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS (EBMT 2026) - Feb 7, 2026 - Abstract #P399; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "Letermovir was given as secondary prophylaxis in 2 patients—patient 1 had multiple episodes of CMV reactivations requiring extended treatment with ganciclovir or foscarnet over 3 months, while patient 4 was started on letermovir after initial PET for CMV reactivation peri-engraftment.2/14 patients developed CS-CMVi during letermovir prophylaxis. Letermovir prophylaxis appears to be safe and effective in our series of paediatric alloHSCT patients. Further research is needed to better define CMV viral load thresholds for initiating PET while on letermovir prophylaxis."
Retrospective data • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Pediatrics • Transplantation
|
|
Yi Xuan Chua1; Su-Fern Michaela Seng1; Xue Fen Valerie Seah1; Karen Donceras Nadua1; Ah Moy Tan1
|